These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33626999)

  • 1. Novel approaches for the management of biliary tract cancer: today and tomorrow.
    Rizzo A
    Expert Opin Investig Drugs; 2021 Apr; 30(4):295-297. PubMed ID: 33626999
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeted Therapy in Biliary Tract Cancers.
    Merla A; Liu KG; Rajdev L
    Curr Treat Options Oncol; 2015 Oct; 16(10):48. PubMed ID: 26266637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical oncologist and liver cancer expert Dr. Tim Pawlik on the potential of pharmacological and surgical approaches in biliary tract cancer.
    Pawlik TM
    Expert Opin Investig Drugs; 2021 Apr; 30(4):299-300. PubMed ID: 33455466
    [No Abstract]   [Full Text] [Related]  

  • 4. Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow.
    Rizzo A; Ricci AD; Tober N; Nigro MC; Mosca M; Palloni A; Abbati F; Frega G; DE Lorenzo S; Tavolari S; Brandi G
    Anticancer Res; 2020 Jun; 40(6):3013-3030. PubMed ID: 32487595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The development of chemotherapy to unresectable advanced biliary tract cancer].
    Arima S; Naruge D; Kasuga A; Kitamura H; Takasu M; Nagashima F; Furuse J
    Gan To Kagaku Ryoho; 2012 Oct; 39(10):1490-3. PubMed ID: 23133874
    [No Abstract]   [Full Text] [Related]  

  • 6. Signaling pathways as therapeutic targets in biliary tract cancer.
    Yang J; Farren MR; Ahn D; Bekaii-Saab T; Lesinski GB
    Expert Opin Ther Targets; 2017 May; 21(5):485-498. PubMed ID: 28282502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Characteristics of Biliary Tract and Primary Liver Tumors.
    Tsai S; Gamblin TC
    Surg Oncol Clin N Am; 2019 Oct; 28(4):685-693. PubMed ID: 31472913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
    Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
    Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ASO Author Reflections: Hypoxia-Induced PLOD2 Is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer.
    Okumura Y; Eguchi H
    Ann Surg Oncol; 2018 Nov; 25(12):3738-3739. PubMed ID: 30167909
    [No Abstract]   [Full Text] [Related]  

  • 10. A foreword on biliary tract cancers: emerging treatments, drug targets, and fundamental knowledge gaps.
    Rizzo A; Brandi G
    Expert Opin Investig Drugs; 2021 Apr; 30(4):279. PubMed ID: 33678120
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeted therapy in biliary tract cancer: 2009 update.
    Tonini G; Virzì V; Fratto ME; Vincenzi B; Santini D
    Future Oncol; 2009 Dec; 5(10):1675-84. PubMed ID: 20001803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-line therapies in advanced biliary tract cancers.
    Tella SH; Kommalapati A; Borad MJ; Mahipal A
    Lancet Oncol; 2020 Jan; 21(1):e29-e41. PubMed ID: 31908303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy and histological stratification of biliary tract cancers.
    Cariati A; Piromalli E
    Oncology; 2012; 82(6):352-3. PubMed ID: 22677952
    [No Abstract]   [Full Text] [Related]  

  • 14. Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial.
    Verlingue L; Malka D; Allorant A; Massard C; Ferté C; Lacroix L; Rouleau E; Auger N; Ngo M; Nicotra C; De Baere T; Tselikas L; Ba B; Michiels S; Scoazec JY; Boige V; Ducreux M; Soria JC; Hollebecque A
    Eur J Cancer; 2017 Dec; 87():122-130. PubMed ID: 29145038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental HER2- targeted therapies for biliary tract cancer.
    Rizzo A; Ricci AD; Bonucci C; Tober N; Palloni A; Frega G; Brandi G
    Expert Opin Investig Drugs; 2021 Apr; 30(4):389-399. PubMed ID: 33218269
    [No Abstract]   [Full Text] [Related]  

  • 16. NRF2: The key to tumor- and patient-dependent chemosensitivity in biliary tract cancer?
    Kiesslich T; Mayr C; Neureiter D
    EBioMedicine; 2019 Nov; 49():9-10. PubMed ID: 31648982
    [No Abstract]   [Full Text] [Related]  

  • 17. [Surgical outcome of biliary tract cancer with neoadjuvant chemotherapy].
    Kato A; Shimizu H; Yoshidome H; Otsuka M; Furukawa K; Yoshitomi H; Takeuchi D; Takayashiki T; Kuboki S; Suzuki D; Nakajima M; Miyazaki M
    Gan To Kagaku Ryoho; 2012 Oct; 39(10):1486-9. PubMed ID: 23133873
    [No Abstract]   [Full Text] [Related]  

  • 18. [Surgical outcome of biliary tract cancer with postoperative chemotherapy].
    Sugawara G; Ebata T; Yokoyama Y; Igami T; Kokuryo T; Tsunoda N; Fukaya M; Uehara K; Itatsu K; Yoshioka Y; Nagino M
    Gan To Kagaku Ryoho; 2012 Oct; 39(10):1483-5. PubMed ID: 23130375
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatobiliary cancer: All efforts for one goal.
    Su C
    Cancer Lett; 2016 Sep; 379(2):164-5. PubMed ID: 27054486
    [No Abstract]   [Full Text] [Related]  

  • 20. Emerging treatment with systemic chemotherapy and targeted agents for biliary cancers.
    Boku N
    Curr Opin Investig Drugs; 2010 Jun; 11(6):653-60. PubMed ID: 20496260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.